00:20 , Dec 22, 2017 |  BC Innovations  |  Product R&D

Dengvaxia’s warning

The fallout of Sanofi’s dengue vaccine debacle has researchers scrambling to rationalize whether competitor products will fall afoul of the same effects, and whether other, related fields should change course. The early upshot is that...
18:42 , Jan 11, 2017 |  BC Week In Review  |  Clinical News

Pertagen regulatory update

Thailand FDA approved an MAA from BioNet-Asia for Pertagen as an active booster immunization against pertussis in people ages ≥11. The company said it is the only recombinant monovalent pertussis vaccine in the world for...
16:16 , Nov 30, 2016 |  BC Week In Review  |  Clinical News

Viaskin rPT: Ph I ongoing

An independent DSMB recommended continuation to the 50 µg cohort of Viaskin rPT in a double-blind, placebo-controlled, Swiss Phase I trial evaluating 48-hour applications of 25 and 50 µg Viaskin rPT given twice 2 weeks...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Viaskin rPT: Phase I started

DBV began a double-blind, placebo-controlled, dose-escalation, Swiss Phase I trial to evaluate two 48-hour applications of 25 and 50 ug Viaskin rPT given 2 weeks apart in about 60 healthy adults. Subjects will receive 1...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Company News

BioNet-Asia management update

BioNet-Asia Co. Ltd. , Bangkok, Thailand   Business: Infectious   Hired: Georges Thiry as COO, effective early 2015, currently director of the Dengue Vaccine Initiative; he will succeed Dario Cresci  ...
08:00 , Dec 19, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

BioNet-Asia, DBV, University of Geneva deal

BioNet, DBV and the university partnered to develop a booster vaccine against pertussis through Phase I proof of concept. The vaccine will combine BioNet's recombinant non-toxic Pertussis Toxin (rPT) with DBV's Viaskin skin patch technology,...